Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.
Autor: | Avramis, Vassilios, Chan, Kenneth, Solorzano, Michelle, Chen, Zhan-liu, Avramis, V I, Chan, K K, Solorzano, M M, Chen, Z L |
---|---|
Předmět: |
PURINE metabolism
ANIMAL experimentation BLOOD proteins COMPARATIVE studies DRUG design CLINICAL drug trials HIGH performance liquid chromatography INJECTIONS INTRAVENOUS injections LYMPHOCYTIC leukemia RESEARCH methodology MEDICAL cooperation MICE PURINES RATS RESEARCH RESEARCH funding TIME EVALUATION research CANCER cell culture |
Zdroj: | Cancer Chemotherapy & Pharmacology; May1993, Vol. 33 Issue 3, p197-202, 6p |
Abstrakt: | O-6-methylguanine (O6-mG), a guanine analog recently shown to be a potent inhibitor of alkylguanine-DNA alkyltransferase, has been found to potentiate the antitumor activity of nitrosoureas, in particular, carmustine (BCNU), in resistant cell lines (HT-29 mer+) and is targeted for development as a modulating agent with chloroethyl nitrosoureas. A high-performance liquid chromatography (HPLC) assay of O6-mG in plasma has been developed using a microC18 reverse-phase column. O6-mG and the internal standard deoxyguanosine (dGuo) were eluted with a linear gradient of from 15% to 35% methanol in 0.5 M ammonium acetate (pH 6.5) at a flow rate of 1 ml/min. The assay was linear over a 4-log concentration range with a detection limit of 0.1 microgram/ml. The within-run and between-run coefficients of variation (CV) were found to be 8.1% and 9.3%, respectively. The pharmacokinetics (PK) of O6-mG were investigated in healthy CDF1 mice following separate i.v. and i.p. administrations. At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1. Higher doses (40-80 mg/kg) revealed a fluctuating third phase, probably due to enterohepatic cycling. Dose-dependent kinetics as measured by CLT and area under the plasma-concentration curve (AUC) values were also seen. Following i.p. dosing, O6-mG was completely absorbed and available to the circulation. No acute toxicity was observed in the animals, except for mild sedation, a possible side effect of the 10% ethanol used in the formulation. Studies on the cellular metabolism of highly purified [3H]-O6-mG have shown that the compound is not anabolized by a human lymphoblastoid cell line (CEM). Biochemistry studies have shown that the parent molecule is inactivating the alkylguanine-DNA alkyltransferase (AGT), thus exerting its pharmacological effect. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |